Anzeige
Mehr »
Login
Samstag, 18.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Spezial Report: NASDAQ-FinTech mit 3.000% Wachstum und 500% Kurs-Chance!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

GlobeNewswire (Europe)-Archiv vom 09.03.2023

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
09.03.23AppHarvest announces 2022 Q4 and full-year results, achieving net sales guidance of $14.6 million388Company successfully quadrupled to a four-farm network in 2022,setting the stage for expected year-over-year sales increases throughout 2023 Company increased net sales by 60% year-over-year MOREHEAD...
► Artikel lesen
09.03.23Nasdaq, Inc.: Nasdaq Announces End of Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date February 28, 2023217NEW YORK, March 09, 2023 (GLOBE NEWSWIRE) -- At the end of the settlement date of February 28, 2023, short interest in 3,441 Nasdaq Global MarketSM securities totaled 10,071,117,158 shares compared...
► Artikel lesen
09.03.23Titan Medical Inc.: Titan Medical Announces Decision of Nasdaq Hearings Panel to Delist Common Shares1.116TORONTO, ON, March 09, 2023 (GLOBE NEWSWIRE) -- Titan Medical Inc. (the "Company" or "Titan") (Nasdaq: TMDI; TSX: TMD) today announced that it has received a decision of the Nasdaq Hearings Panel (the...
► Artikel lesen
09.03.23SAVENCIA: 2022 Annual Results524Thursday, March 9, 2023 PRESS RELEASE: 2022 annual financials Sales increase by 16.8%Net income Group share down to € 68 millionControlled indebtedness Key figures in €M 12/31/22...
► Artikel lesen
09.03.23Icelandair Group hf.: Results of the Annual General Meeting900Icelandair Group's Annual General Meeting was held today at 4pm and the results were as follows: Annual Accounts (Item 2) The Board of Directors proposed to the Annual General Meeting that the Annual...
► Artikel lesen
09.03.23Magic Software Enterprises Ltd.: Magic Software Reports Fourth Quarter and Full Year 2022 Financial Results with Record-Breaking Full Year 2022 Results Recorded Across All Key Financial Indices (Revenues, Gross Profit, Operating Income and Net Income)288OR YEHUDA, Israel, March 09, 2023 (GLOBE NEWSWIRE) -- Magic Software Enterprises Ltd. (NASDAQ and TASE: MGIC) ("the Company"), a global provider of IT consulting services and end-to-end integration...
► Artikel lesen
09.03.23Groupe Casino: TERACT and Casino Group sign an exclusive agreement to create the French leader in responsible and sustainable retail activities375TERACT and Casino Group sign an exclusive agreement to create the French leader in responsible and sustainable retail activities Paris, March 9th 2023, TERACT and Casino Group announce that they have...
► Artikel lesen
09.03.23Molecular Partners Reports Corporate Highlights From Q4 2022 and Key Financials for Full Year 2022426Research & Development Highlights: Initiated Phase 1 study of MP0533, a novel tri-specific T-cell engager for the treatment of acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS)Presented...
► Artikel lesen
09.03.23Global Crossing Airlines Group Inc.: Global Crossing Airlines Announces $97.1M in Revenue for 2022286Q4 Adjusted EBITDAR of $5.2MForecasts over $140M in Revenue for 2023 MIAMI, March 09, 2023 (GLOBE NEWSWIRE) -- Global Crossing Airlines Group, Inc. (JET: NEO; JET.B: NEO; JETMF: OTCQB) (the "Company"...
► Artikel lesen
09.03.23aTyr Pharma, Inc.: aTyr Pharma Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update380Phase 3 EFZO-FIT study of efzofitimod in patients with pulmonary sarcoidosis enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected...
► Artikel lesen
09.03.23Olema Oncology Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Strategic Update249Significant progress made advancing lead program, OP-1250, with more than 170 patients treated to date Initiating first pivotal Phase 3 monotherapy clinical trial of OP-1250 in second- and third-line...
► Artikel lesen
09.03.23Frequency Electronics, Inc. Announces Third Quarter Fiscal Year 2023 Financial Results342MITCHEL FIELD, N.Y., March 09, 2023 (GLOBE NEWSWIRE) -- Frequency Electronics, Inc. ("FEI" or the "Company") (NASDAQ-FEIM) is reporting revenues for the three- and nine-month periods of fiscal 2023...
► Artikel lesen
09.03.23Gevo, Inc.: Gevo Reports Fourth Quarter 2022 Financial Results563ENGLEWOOD, Colo., March 09, 2023 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) ("Gevo", the "Company", "we", "us" or "our") today announced financial results for the fourth quarter of 2022 and recent...
► Artikel lesen
09.03.23Research Frontiers Incorporated: Research Frontiers Reports Fourth Quarter and Year-End 2022 Financial Results and Will Host a Conference Call at 4:30p.m. Today344WOODBURY, N.Y., March 09, 2023 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR) announced its financial results for its fourth quarter and full year 2022. Management will host a conference...
► Artikel lesen
09.03.23ALX Oncology Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones221SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block...
► Artikel lesen
09.03.23Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2022 Financial Results232Encouraging and improving interim Phase 1/2 study results for zilovertamab plus ibrutinib in patients with MCL and CLL, including those with mutated TP53 and/or del(17p), presented at ASH in December...
► Artikel lesen
09.03.23VYNE Therapeutics Inc.: VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update396First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09, 2023...
► Artikel lesen
09.03.23Yellow Corporation Provides Quarter-To-Date Operating Data for First Quarter 2023455 NASHVILLE, Tenn., March 09, 2023 (GLOBE NEWSWIRE) -- Yellow Corporation (NASDAQ: YELL) reported certain operating metrics for the first two months of first quarter 2023. For Yellow less-than-truckload...
► Artikel lesen
09.03.23Aptose Biosciences, Inc.: Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023190SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors...
► Artikel lesen
09.03.23Aware, Inc.: Aware Reports Fourth Quarter and Full Year 2022 Financial Results349BURLINGTON, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Aware, Inc. (NASDAQ: AWRE), a leading authentication company applying proven and trusted adaptive authentication to solve everyday business challenges...
► Artikel lesen
Seite:  Weiter >>